Clinical trials: MS
Multiple Sclerosis
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.
- Trial name
- START (NCT01585298)
- Testing
- FTY720
- Where
- 258 sites in Germany
- Volunteers
- 6,998 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
The purpose of this study is to determine whether raltegravir is effective in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium- enhanced MRI.
- Trial name
- INSPIRE (NCT01767701)
- Testing
- Raltegravir
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study
The Main Hypothesis of this extension trial is that among those who have successfully discontinued their DMT as part of the DISCOMS trial (i.e.
- Trial name
- NCT04754542
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis (MS)
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
- Trial name
- RELEASE MSS3 (NCT04203498)
- Testing
- Nabiximols
- Where
- 37 sites in United States, Czechia and 3 more
- Volunteers
- 139 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who…
- Trial name
- NCT00648908
- Testing
- Fampridine-SR
- Where
- 32 sites in United States, Canada
- Volunteers
- 269 people
- Sponsor
- Acorda Therapeutics
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration.
- Trial name
- Operetta 2 (NCT05123703)
- Testing
- Ocrelizumab, Fingolimod
- Where
- 71 sites in United States, Argentina and 23 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact Scale {GGISIS}) in assessing GI tolerability…
- Trial name
- NCT03093324
- Testing
- ALKS 8700, Dimethyl Fumarate
- Where
- 67 sites in United States, Germany and 1 more
- Volunteers
- 506 people
- Sponsor
- Biogen
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, [F-18]PBR06 and…
- Trial name
- NCT04144257
- Testing
- [F-18]PBR06, [C-11]Methylreboxetine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Progressive Multiple Sclerosis
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS).
- Trial name
- NCT03423121
- Testing
- Tauroursodeoxycholic Acid
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Johns Hopkins University
Relapsing-Remitting Multiple Sclerosis
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord.
- Trial name
- NCT00288626
- Testing
- Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
- Trial name
- NCT03737812
- Testing
- elezanumab
- Where
- 37 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- AbbVie
Multiple Sclerosis, Spasticity, Muscle
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) that is regarded as the foremost cause of non-traumatic neurologic disability in adults in North America.
- Trial name
- OS440-3004 (NCT03290131)
- Testing
- Arbaclofen
- Where
- 30 sites in Belarus, Bosnia and Herzegovina and 5 more
- Volunteers
- 536 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Neuropathic Pain, Chronic Pain
Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis
This study will determine whether treatment with an extended-release opioid or topical lidocaine is effective in relieving distal symmetric lower extremity burning pain associated with multiple sclerosis (MS).
- Conditions
- Neuropathic Pain, Chronic Pain, Multiple Sclerosis
- Trial name
- NCT00414453
- Testing
- Lidocaine patch 5%, Extended-release oxycodone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Rochester
Multiple Sclerosis
Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS
Multiple sclerosis (MS) is the leading cause of irreversible neurological disability among young women and the second leading cause of disability among young men in the U.S.
- Trial name
- ABC's of MS (NCT03808545)
- Testing
- Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS), BIPAMS + Diet
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Alabama at Birmingham
Multiple Sclerosis, Relapsing-Remitting
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.
- Trial name
- NCT01909492
- Testing
- Blood Draw, Lumbar Puncture
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Providence Health & Services
Rheumatoid Arthritis
Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)
This study is multicenter, Ph IV, single arm, interventional study to assess relative reduction of morning stiffness of Lodotra® in Rheumatoid Arthritis patients.Study medication will start after study visit at baseline (week 0…
- Trial name
- NCT02072200
- Testing
- Lodotra®
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Mundipharma Korea Ltd
Multiple Sclerosis
Protective Stepping in People With MS
Falls are common in Veterans with multiple sclerosis (MS), and current rehabilitation approaches to reduce falls are inadequate.
- Trial name
- PRO-STEP (NCT03551665)
- Testing
- Protective step training
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Fatigue
Ketamine for Treatment of MS Fatigue
Multiple sclerosis (MS) is an inflammatory, demyelinating and degenerative disease of the central nervous system and, after trauma, is the most common cause of disability in young adults, affecting more than 400,000 individuals…
- Trial name
- NCT03500289
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
Memantine for Spasticity in MS Patients
Participants (n=20) will be identified at routine care visits performed at the Rochester Multiple Sclerosis Center. Eligible participants will have MS by McDonald Criteria,7 and will have a modified Ashworth spasticity rating8 of…
- Trial name
- NCT00638027
- Testing
- memantine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Rochester